MRNS - Marinus Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.2600
-0.0400 (-1.74%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close2.3000
Open2.3400
Bid2.2200 x 1400
Ask2.2600 x 3100
Day's Range2.2200 - 2.3900
52 Week Range0.7700 - 5.4000
Volume689,011
Avg. Volume1,602,035
Market Cap195.492M
Beta (5Y Monthly)3.13
PE Ratio (TTM)N/A
EPS (TTM)-0.9770
Earnings DateNov. 05, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.38
  • GlobeNewswire

    Marinus Provides Business Outlook for 2020

    Enrollment on-track for CDKL5 Deficiency Disorder Phase 3 readout Q3 2020 Two additional late-stage clinical trials planned to initiate in 2020 Company presentation and live.

  • GlobeNewswire

    Marinus Pharmaceuticals to Present at the 38th Annual J.P. Morgan Global Healthcare Conference

    RADNOR, Pa., Jan. 07, 2020 -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), (Nasdaq: MRNS) (“Marinus” or “Company”), a pharmaceutical company dedicated to the development of.

  • Marinus Pharmaceuticals (MRNS) Catches Eye: Stock Jumps 7.7%
    Zacks

    Marinus Pharmaceuticals (MRNS) Catches Eye: Stock Jumps 7.7%

    Marinus Pharmaceuticals (MRNS) shares rose nearly 8% in the last trading session, amid huge volumes.

  • Implied Volatility Surging for Marinus Pharmaceuticals (MRNS) Stock Options
    Zacks

    Implied Volatility Surging for Marinus Pharmaceuticals (MRNS) Stock Options

    Investors need to pay close attention to Marinus Pharmaceuticals (MRNS) stock based on the movements in the options market lately.

  • GlobeNewswire

    Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the Board of Directors of Marinus granted non-qualified stock options to purchase an aggregate of 121,000 shares of its common stock to new employees, with a grant date of December 11, 2019. The stock options were granted as inducements material to the new employees entering into employment with Marinus in accordance with NASDAQ Listing Rule 5635(c)(4), and are subject to the terms and conditions of a stock option agreement covering the grant. Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and depression.

  • GlobeNewswire

    Marinus Pharmaceuticals Announces Closing of $70 Million Public Offering of Common Stock and Concurrent Private Placement Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

    The offering included participation from new and existing investors, and together with the concurrent private placement raised gross proceeds of approximately $70 million, before deducting underwriting discounts and commissions, placement agent fees and estimated offering expenses payable by the Company. Craig-Hallum Capital Group LLC acted as co-manager for the offering. Concurrently with the completion of the public offering, the Company sold to certain investors in a private placement, a number of shares of convertible preferred stock equal to an aggregate purchase price of up to $30 million, at a conversion price of $1.25 per share.

  • GlobeNewswire

    Marinus Pharmaceuticals Appoints Elan Ezickson to Board of Directors

    Mr. Ezickson is a highly accomplished executive with over 30 years of experience in the life sciences industry across commercial, operational and strategic leadership roles. “We are thrilled to welcome Elan to our board of directors,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus.

  • GlobeNewswire

    Corrected Press Release: Marinus Pharmaceuticals Announces Pricing of $65 Million Public Offering of Common Stock and Concurrent Private Placement

    The gross proceeds to the Company from the public offering and concurrent private placement are expected to be approximately $65 million before deducting underwriting discounts and commissions, placement agent fees, and other estimated offering expenses. The Company has granted to the underwriters participating in the offering a 30-day option to purchase up to an additional 4,200,000 shares of common stock.

  • GlobeNewswire

    Marinus Pharmaceuticals Announces Pricing of $65 Million Public Offering of Common Stock and Concurrent Private Placement

    The gross proceeds to the Company from the public offering and concurrent private placement are expected to be approximately $65 million before deducting underwriting discounts and commissions, placement agent fees, and other estimated offering expenses. The Company has granted to the underwriters participating in the offering a 30-day option to purchase up to an additional 4,200,000 shares of common stock.

  • GlobeNewswire

    Marinus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

    All of the shares in the offering are to be sold by Marinus. Marinus also expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of shares to be issued and sold in the public offering. Concurrently with the completion of the public offering, the Company expects to sell to certain investors in a private placement, a number of shares of convertible preferred stock equal to an aggregate purchase price of up to approximately $30 million, at a price equal to the public offering price.

  • GlobeNewswire

    Marinus Announces Ganaxolone Orphan Epilepsy Program Updates Including Planned Clinical Program in Tuberous Sclerosis Complex

    Initiation of Phase 2 trial evaluating ganaxolone in tuberous sclerosis complex planned for 1H 2020 European Medicines Agency Orphan Drug Designation granted for ganaxolone for.

  • GlobeNewswire

    Marinus Presents Additional Data from Ganaxolone Phase 2 Trial in Refractory Status Epilepticus at the American Epilepsy Society Annual Meeting

    100% of evaluable patients in target dose had no relapse during the four-week follow-up period Independent objective EEG seizure analysis confirms target dose Ganaxolone.

  • GlobeNewswire

    Marinus Pharmaceuticals Announces Presentations on Ganaxolone at AES Annual Meeting

    Marinus Pharmaceuticals, Inc. (MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that two abstracts highlighting ganaxolone data have been selected for poster presentation at the American Epilepsy Society (AES) Annual Meeting in Baltimore, Maryland on December 7 and 8, 2019.

  • GlobeNewswire

    Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the Board of Directors of Marinus granted non-qualified stock options to purchase an aggregate of 400,000 shares of its common stock to a new employee, with a grant date of November 7, 2019. The stock options were granted as an inducement material to the new employee entering into employment with Marinus in accordance with NASDAQ Listing Rule 5635(c)(4), and are subject to the terms and conditions of a stock option agreement covering the grant. Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and depression.

  • GlobeNewswire

    Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter Financial Results

    Positive Phase 2 IV ganaxolone data in RSE Strong enrollment continues in pivotal CDD study RADNOR, Pa., Nov. 06, 2019 -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a.

  • GlobeNewswire

    Marinus Pharmaceuticals Appoints Joe Hulihan, M.D., as Chief Medical Officer

    Marinus Pharmaceuticals, Inc. (MRNS) (“Marinus” or “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders, today announced that Joe Hulihan, MD, has been appointed Chief Medical Officer. Dr. Hulihan will succeed outgoing CMO, Lorianne Masuoka, MD, who is retiring from the position. “On behalf of the entire Marinus team and Board of Directors, I welcome Joe at this exciting time at Marinus and thank Lorianne for her dedicated service,” said Scott Braunstein, MD, Chief Executive Officer of Marinus.

  • GlobeNewswire

    Marinus Phase 2 Clinical Data on Ganaxolone in RSE Presented at Neurocritical Care Society Meeting

    Marinus Pharmaceuticals, Inc. (MRNS) (“Marinus” or “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders, today announced that results from its Phase 2 trial of ganaxolone in Refractory Status Epilepticus (RSE) were presented at the Neurocritical Care Society 17th Annual Meeting in Vancouver, BC. The results were featured in an oral platform presentation by Henri Vaitkevicius M.D., investigator in the study.  As previously disclosed, ganaxolone met the primary endpoint in the study with none of the 17 patients progressing to IV anesthetics within 24 hours of treatment initiation. A target dose of ganaxolone has been identified for advancement to Phase 3 and this is supported by pharmacokinetic (PK) data, presented for the first time at the meeting today.

  • GlobeNewswire

    Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the Board of Directors of Marinus granted non-qualified stock options to purchase an aggregate of 15,000 shares of its common stock to a new employee, with a grant date of September 12, 2019. The options have an exercise price of $1.69 per share, which is equal to the closing price of Marinus’s common stock on September 12, 2019, the date of grant. The options will vest and become exercisable as to 25 percent of the shares on the one-year anniversary of the recipient's start date, and will vest and become exercisable as to the remaining 75 percent of the shares in 36 equal monthly installments at the end of each month following the anniversary, subject to the employee's continued employment with Marinus on such vesting dates.  The stock options were granted as inducements material to the new employee entering into employment with Marinus in accordance with NASDAQ Listing Rule 5635(c)(4), and are subject to the terms and conditions of a stock option agreement covering the grant.

  • GlobeNewswire

    Marinus Pharmaceuticals Announces Positive Top-Line Results With Ganaxolone in Phase 2 Refractory Status Epilepticus Trial

    Marinus Pharmaceuticals, Inc. (MRNS) (“Marinus” or “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders, today announced that it has completed the top-line analysis of the open-label, dose-finding Phase 2 study evaluating intravenous (IV) ganaxolone in patients with refractory status epilepticus (RSE). Ganaxolone met the primary endpoint in the study with no patients (n=17) progressing to IV anesthetics within 24 hours of treatment initiation.

  • Is the Options Market Predicting a Spike in Marinus (MRNS) Stock?
    Zacks

    Is the Options Market Predicting a Spike in Marinus (MRNS) Stock?

    Investors need to pay close attention to Marinus Pharmaceuticals (MRNS) stock based on the movements in the options market lately.

  • Is Marinus Pharmaceuticals (NASDAQ:MRNS) In A Good Position To Invest In Growth?
    Simply Wall St.

    Is Marinus Pharmaceuticals (NASDAQ:MRNS) In A Good Position To Invest In Growth?

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

  • Are Options Traders Betting on a Big Move in Marinus (MRNS) Stock?
    Zacks

    Are Options Traders Betting on a Big Move in Marinus (MRNS) Stock?

    Investors need to pay close attention to Marinus (MRNS) stock based on the movements in the options market lately.

  • GlobeNewswire

    Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter Financial Results

    Marinus Pharmaceuticals, Inc. (MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its clinical development activities and reported its financial results for the second quarter ended June 30, 2019. “I am proud to announce that after an extensive interview process with several qualified candidates, the Board has appointed me as Chief Executive Officer of Marinus,” commented Dr. Scott Braunstein, formerly Executive Chairman of Marinus.  “As Executive Chairman, the past six months have been both invigorating and challenging as I worked with the Marinus team to continue to unlock the value potential of ganaxolone.

  • Here's Why Marinus Pharmaceuticals Stock Is Collapsing Today
    Motley Fool

    Here's Why Marinus Pharmaceuticals Stock Is Collapsing Today

    Wall Street is not sold on the latest clinical results.